FDB OptimiseRx™

Prescribers Guide: EMIS Web

FDB OptimiseRx is fully integrated into the prescribing workflow within EMIS Web. OptimiseRx uses the medication prescribed, and in some cases the supplied quantity or patient specific criteria, medication and condition history to determine whether an OptimiseRx message is relevant to present to the prescriber at the point of care.

OptimiseRx messages may appear when initiating a medication for the first time, reauthorisation of individual or multiple medications, regime review and restarting a previous medication.

There are three types of message that could be presented when a medication is selected:

- Formulary
- Best Practice Guidance or Cost Saving (where there are multiple Alternative Products)
- Information e.g. monitoring guidance

A further message type may be displayed at the end of the prescribing workflow after completion of dosage and quantity information and these are referred to as Simple Cost Messages.

Best Practice Guidance messages or Cost Saving messages with multiple Alternative Products

Click to expand to reveal the full message   **Headline Message**   **Click this box to reveal the Alternative Products**

Icon indicates Best Practice or Cost Saving messages   **Reject button for individual messages**

fdb®
First Databank

Click to access the source Best Practice Guidance

Selected drug - **Diclofenac potassium 50mg tablets**

| - | | Review choice of NSAID/COX-2 (cyclo-oxygenase) inhibitor; consider ibuprofen or naproxen. | ✔ Accept | ✗ Reject |

Source   View reference information

NICE key therapeutic topic (KTT13, January 2017) summarises the evidence-base on NSAIDs. It notes that the lowest effective dose of NSAIDs or COX-2 inhibitors should be prescribed for the shortest duration necessary to control symptoms. Evidence indicates that low dose ibuprofen (up to 1200mg per day) or naproxen (up to 1000mg per day) may be associated with a lower cardiovascular risk.
LOCAL TEXT: Please See link for local guidances

View the triggered rule for this patient

Click to view the patient attributes which triggered the message

To display and select from the Alternative Products list

Click the box to reveal the Alternative Products

Selected drug - **Diclofenac potassium 50mg tablets**

| - | | Review choice of NSAID/COX-2 (cyclo-oxygenase) inhibitor; consider ibuprofen or naproxen. | ✔ Accept | ✗ Reject |

Source   View reference information

NICE key therapeutic topic (KTT13, January 2017) summarises the evidence-base on NSAIDs. It notes that the lowest effective dose of NSAIDs or COX-2 inhibitors should be prescribed for the shortest duration necessary to control symptoms. Evidence indicates that low dose ibuprofen (up to 1200mg per day) or naproxen (up to 1000mg per day) may be associated with a lower cardiovascular risk.
LOCAL TEXT: Please See link for local guidances

View the triggered rule for this patient

| + | | Consider prescribing diclofenac so... potassium 50mg tablets. | | Reject |

Alternative drugs   ×
- ○ Ibuprofen 400mg tablets
- ○ Naproxen 250mg tablets
- ○ Naproxen 500mg tablets

Proceed   Cancel

Disclaimer: The Medicines Optimisation module is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance. View full disclaimer.

Proceed   Cancel

List of Alternatives Products
1. Click on the chosen Alternative Product
2. Click proceed

fdb First Databank

Rejecting a Message

On rejecting a message the prescriber is presented with the option to enter a rejection reason. Click Reject to proceed without entering any text.

This is an optional step but any text entered here will be available to colleagues in the medicines management team to assist in managing the configuration of OptimiseRx. NB Text entered here may also be recorded in the detailed drug history and patient medical record.

fdb®

First Databank

Simple Cost Saving Messages

Simple Cost Saving messages will appear once the quantity and dosage information has been entered as this is used to calculate that a saving is available. The savings presented are 'per dose unit' and therefore do not reflect the actual saving potential from accepting the message.

<table>
<tr><td colspan="2">⚠ A more cost-effective alternative drug could be used.</td></tr>
<tr><td>Original drug</td><td>Recommended alternative</td></tr>
<tr><td>Name Erythromycin 250mg gastro-resistant capsules</td><td>Name Erythromycin 250mg gastro-resistant tablets</td></tr>
<tr><td>Class Generic</td><td>Class Generic</td></tr>
<tr><td>Cost £5.61</td><td>Cost £1.28</td></tr>
<tr><td colspan="2" align="center">Saving £4.33</td></tr>
</table>

Disclaimer: The Medicines Optimisation module is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance. View full disclaimer.

[Proceed with alternative] [Proceed with original] [Do not proceed]

Replaces the original drug with the Alternative Product in the prescribing screen. Where an appropriate dose string match is found in EMIS Web the dosage will be carried forward on to the Alternative Product.

Returns to the drug selection prescribing screen.

Continues prescribing of the original selected drug

To Acknowledge an Information Message

The Best Practice guidance in an Information message can be acknowledged by clicking OK.

Selected drug - **Metformin 500mg tablets**

[+] ℹ️ **Monitor the patient's serum creatinine; no result recorded within 1 year.**

Disclaimer: The Medicines Optimisation module is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance. View full disclaimer.

[OK]

fdb® First Databank

Formulary Message

Click here to expand to see more detail on why this message has appeared for this medication.

Your local organisation may have provided a hyperlink to the local formulary or other Best Practice guidance.

Selected drug - **Adoport 0.5mg capsules (Sandoz Ltd)**

The selected product is classified as RED.

Source

Only suitable for use within hospital or specialist care setting.

View reference information

View the triggered rule for this patient

Disclaimer: The Medicines Optimisation module is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance. View full disclaimer.

OK

Click OK to continue prescribing a medication that has a local formulary message associated with it.

fdb
First Databank